Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANAVEX LIFE SCIENCES CORP. Director's Dealing 2025

Oct 4, 2025

32464_dirs_2025-10-03_d359de83-3bf8-4e39-a692-583fe3f67c9d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANAVEX LIFE SCIENCES CORP. (AVXL)
CIK: 0001314052
Period of Report: 2025-10-02

Reporting Person: MISSLING CHRISTOPHER U (Director, President and CEO)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-10-02 Stock Option (Right to Buy) $5.36 A 125000 Acquired 2034-02-20 Common Stock (125000) Direct

Footnotes

F1: On February 20, 2024, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Readout of AV3-71-SZ-001 schizophrenia study. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.